Oppenheimer Initiates Coverage of Viatris and Teva with Outperform Ratings
On September 22, Oppenheimer initiated coverage on both Viatris (VTRS) and Teva Pharmaceutical Industries (TEVA), assigning them 'Outperform' ratings. The firm set a price target of $25 for Viatris, representing approximately 46% upside from its closing price at the time. For Teva, Oppenheimer's price target is $50, implying about 27% potential growth. The analyst behind this recommendation did not provide detailed reasoning in the excerpt but typically such ratings reflect confidence in a company’s fundamentals or strategic direction. Viatris and Teva are both major players in the generic drug sector, where pricing pressures and regulatory changes often influence stock performance.
Topics: Pharmaceuticals Stock Analysis